

Curriculum Vitae - David Nicol

PERSONAL DETAILS

SURNAME: NICOL

FORENAMES: David Leslie

DATE OF BIRTH: 26th December 1960

TERTIARY EDUCATION & QUALIFICATIONS:

1983 MBBS – University of Queensland (UQ),
Brisbane, AUST

1991 FRACS

CURRENT APPOINTMENTS:

**Consultant Urologist and Chief of Surgery 2012 -
Royal Marsden Hospital**
Fulham Road London SW3 6JJ

**Professor of Surgical Oncology 2015 -
Institute of Cancer Research**
Fulham Rd
London SW3 6JB

Honorary Professor 2011 - 2016
Division of Surgery and Interventional Science,
University College London, London, UK

Professor of Surgery 2006 -
University of Queensland (UQ), Brisbane

PREVIOUS APPOINTMENTS

:

CONSULTANT

2009 – 2012 **Clinical Lead Renal Transplantation & Consultant Urologist**
Royal Free Hospital
University College Hospital
London, UK

1992 – 2009 **Director of Urology & Renal Transplantation**
Princess Alexandra Hospital - Brisbane, AUST

2005 – 2012 **Professor of Urology**
School of Life Sciences
Queensland University of Technology (QUT),
Brisbane

FELLOWSHIP 1991

Multi-organ Transplant Program
Victoria General Hospital, Halifax NS,
CANADA

RESIDENCY

1990 Urology Registrar
Princess Alexandra Hospital, Brisbane, AUST

1989 Urology Registrar
Greenslopes Repatriation Hospital, Brisbane,
AUST

1988 Urology Registrar
Royal Brisbane Hospital, Brisbane, AUST

1987 Surgical Registrar
Princess Alexandra Hospital, Brisbane, AUST

1986 Surgical Registrar
Princess Alexandra Hospital, Brisbane, AUST

**PROFESSIONAL
MEMBERSHIPS:**

1996 – 2001	Member Board of Urology, Urological Society of Australia & New Zealand
1998 – 2001	Committee Member Australian & New Zealand Dialysis and Transplant Registry
1998 – 2001	Executive Member Urological Society of Australia & New Zealand
2005 - 2009	Executive Member Section of Transplant Surgery, Royal Australasian College of Surgery
2006 - Current	Board Member Kidney Cancer Association (USA)
Current	British Medical Association
Current	Transplantation Society of Australia & New Zealand
Current	American Urological Association
Current	Urological Research Society
Current	The Transplant Society
Current	British Association of Urological Surgeons
Current	British Transplant Society
Current	European Society of Organ Transplantation

AWARDS: 1995, 2005 Alban Gee Prize
1998, 2000 British Association of Urological Surgeons Prize
1998, 1999 Bruce Pearson Fellow
2003 Australian Kidney Foundation Prize

Completed PhD's Supervised/Co-Supervised

Su-Ing Hii (UQ) 2002

Studies on the role of vascular endothelial growth factors in renal cell carcinoma.

- Janet Louise Reid (UQ) 2002
The mechanism of action of captopril in human renal cell carcinoma.
- Catherine Cheung (UQ) 2005
IGF family members in renal cell carcinoma
- Bronwyn Bulmer (QUT) 2001
Prostate specific antigen-like expression in renal cell carcinoma.
- Fiona Rae (QUT) 2001
Identification and characterisation of genes expressed in renal cell carcinoma.
- Tara Veveris-Lowe (QUT) 2003
Characterisation of prostate-specific antigen (PSA) and kallikrein 2 in the progression of prostate cancer.
- Mitchell Lawrence (QUT) 2009
Crosstalk between developmental and tumour-specific signalling pathways : kallikrein-related serine peptidases in prostate cancer
- Ian Vela (UQ) 2011
Wnt pathway interactions in prostate cancer bone metastases

PROFESSIONAL AND EXTERNAL DEVELOPMENT ACTIVITIES

Professional Activities

- 1995 – 2009 Examiner
Australian Medical Council
- 1998 – 2001 Chairman
Continuing Medical Education
Urological Society of Australia & New Zealand
- 2002 – 2009 Examiner
Royal Australasian College of Surgeons
- 2003 – 2013 Editorial Board Member
British Journal of Urology (BJU) International
- 2008 – 2013 Associate Editor
British Journal of Urology (BJU) International
- 2013 – 2016 Member
Specialist Urology Commissioning Group NHS England
- 2009 - Consulting Editor
Urologic Oncology
- 2017 - Member
National Cancer Research Institute - Kidney and Bladder Cancer Clinical Specialty Group
- 2018 - Member
EAU Testicular Cancer Guidelines Committee

International Government Consultancies

- 2008 Ministry of Health - Brunei Darussalam
‘Feasibility and proposal for establishment of renal transplant services in Brunei Darussalam’

PUBLICATIONS

Book Chapters

1. Integrating Molecular, Proteomic and Vaccine Development, Quality of Life and Psychometric Evaluations in a Comprehensive Research Program; Gardiner RA, Burger MJ, Schmidt, Steginga C, **Nicol DL**, Walsh T, Lavin MF, Clements JA. (pp 189 – 216) in PROSTATE CANCER Edited by John N Lucas; Nova Publishers 2004.
2. Adult Urinary Tract Infections; Malone GJ, **Nicol DL**. (pp 121-164); In MANAGEMENT OF UROLOGICAL EMERGENCIES Edited by Faiz Mumtaz, Christopher RJ Woodhouse, Jack W McAninch, Dennis L Cochlin; Taylor & Francis 2004.
3. Supportive Care for the Renal Transplant Patient; **Nicol DL**, Martin C; (chapter 19) in SUPPORTIVE CARE OF THE UROLOGY PATIENT Edited by Richard W Norman & David C Currow; Oxford University Press 2005.
4. Models of Human Renal Cell Carcinoma; Meaghan L., Douglas and **David L. Nicol**; (pp 539 – 550); in RENAL CELL CANCER, DIAGNOSIS AND THERAPY Edited by JJMCHdI Rosette, CN Sternberg & HPAv Poppel; Springer 2008.
5. Use of analogies to assist with explanation of urological problems Nicol D in TOP TIPS IN UROLOGY Edited by John McLoughlin Wiley Blackwell 2013
6. Renal Cell Carcinoma Boleti E and Nicol D, PRACTICAL NEPHROLOGY Edited by Harber M Springer (2014)

Peer Reviewed Journals

1. **Nicol D**, Cohen AD, Bitter-Suermann HS, Belitsky P, MacDonald AS. Combination therapy with CMV hyperimmune globulin and low dose Acyclovir reduces the risk of primary CMV disease in renal transplantation. Transplantation 1993; 55: 841.
2. **Nicol D**, MacDonald AS, Lawen J, Belitsky P. Early prediction of renal allograft loss beyond one year. Transplant Int. 1993 May; 6(3): 153-157.
3. **Nicol D**, Heathcote PS, Kateley D, Lloyd S. Advanced prostate cancer: The role of high priced hormone therapy. Med J Aust. 1993 July 5; 159(1): 16-19.
4. Sketris I S, Onarato L, Yatscoff RW, Givner D, **Nicol D**, Abraham I. Cyclosporine overdose. Pharmacotherapy. 1993 Nov-Dec; 13(6): 658-660.
5. **Nicol D**, P'Ng KBF, Hardie DR, Wall DR, Hardie IR. Routine use of indwelling ureteric stents in renal transplantation. J Urol. 1993 Nov; 150(5 Pt 1): 1375- 1379.
6. **Nicol D**, Winkle D, Nathanson L, Smithers M. Laparoscopic nephrectomy for benign renal disease. BJU Int. 1994 Mar; 73(4): 237-241.
7. **Nicol D**, Teh B, Strachan N, Ward G, Martin N. Familial testicular carcinoma: In search of genetic triggers. Aust NZ J Surg. 1994 June; 64(6): 418-420.

8. Sketris S, Methot ME, **Nicol D**, Belitsky P, Knox MG. Effect of calcium-channel blockers on cyclosporine clearance in renal transplant patients. *Ann Pharmacother*. 1994 Nov; 28(11): 1227-1231.
9. **Nicol DL**, Smithers BM. Laparoscopic approach to the left kidney avoiding colonic mobilization. *J Urol*. 1994 Dec; 152(6 Pt 1): 1967-1969.
10. **Nicol D**, Ward JW, McMullin RW, Moss DM. Urological training in Australasia - perceptions of recent fellows and current trainees. *Aust NZ J Surg*. 1995 Apr; 65(4): 278-283.
11. Preston J, Axelsen R, Quinn J, Wall D, **Nicol D**. Donor related secondary haemorrhage complicating renal transplantation. *Transplant Int*. 1995; 8(5): 403-406.
12. **Nicol D**. Urological aspects of renal transplantation. *Current Opinion in Urology* 1995; 5: 86-90.
13. **Nicol DL**. BCG in bladder cancer. *Aust NZ J Med* 1995 Aug; 25(4): 275-277.
14. Thong W, Hinsch R, Clouston A, **Nicol D**. Nephrogenic metaplasia: Long term haemodialysis and anuria are potential risk factors and reversibility with renal transplantation. *Neph Dial Transpl* 1995 Nov; 10(11): 2101-2103.
15. Olive C, **Nicol D**, Falk M. Characterisation of $\alpha\alpha$ T cells in renal cell carcinoma patients by PCR analysis of T cell receptor transcripts. *Cancer Immunol Immunother* 1997 Mar; 44(1): 27-34.
16. Teh B, Giraud S, Sari NF, Hii S, Bergerat J, Larsson C, Limacher JM, **Nicol D**. Familial non-VHL, non papillary clear-cell renal cancer. *Lancet* 1997 Mar 22; 349(9055): 848-849.
17. Olive C, **Nicol D**, Falk MC. Characterisation of gamma delta T cells in renal cell carcinoma patients by polymerase chain reaction analysis of T cell receptor transcripts. *Cancer Immunol Immunother*. 1997 Mar; 44(1): 27-34
18. **Nicol D**, Hii S-I, Walsh M, Teh B, Thompson L, Kennett C, Gotley D. Vascular endothelial growth factor expression is increased in renal cell carcinoma. *J Urol* 1997 Apr; 157(4): 1482-1486.
19. Clements J, Ward G, Kaushal A, Hii SI, Kenneth C, **Nicol D**. A prostate-specific antigen-like protein associated with renal cell carcinoma in women. *Clin Cancer Res* 1997 Aug; 3(8): 1427-1431.
20. Mizusawa Y, Parnham AP, Falk MC, Burke JR, **Nicol D**, Yamanaka J, Lynch SV, Strong RW. Potential for bilateral nephrectomy to reduce oxalate release after combined liver and kidney transplantation for primary hyperoxaluria type 1. *Clin Transplant*. 1997 Oct; 11(5 Pt 1): 361-365.
21. Gardiner RA, Spork R, **Nicol D**. Long-term experience with endoscopic transvesical ureterotomy. *Min Invas Ther & Allied Technol* 1997; 5/6: 479-483.
22. Swindle P, Falk M, Rigby R, Petrie J, Hawley C, **Nicol D**. Transitional cell carcinoma in renal transplant recipients: The influence of compound analgesics. *BJU Int* 1998 Feb; 81(2): 229-233.
23. Teh BT, Blennow E, Giraud S, Sahlen S, Hii S, Brookwell R, Brauch H, Nordenskjöld M, Larsson C, **Nicol D**. Bilateral multiple renal oncocytomas and cysts associated with a constitutional translocation (8;9) (q24.1;q34.3) and a rare constitutional VHL missense substitution. *Gene Chromosome Cancer* 1998 Mar; 21(3): 260-264.

24. Hii S-I, **Nicol D**, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. *Br J Cancer* 1998 Mar; 77(6): 880-883.
25. Wood GA, Heathcote PS, **Nicol D**. Bowel motility after enterocystoplasty. *BJU Int* 1998 Apr; 81(4): 565-568.
26. Heathcote PS, Mactaggart P, Boston RJ, James AN, Thompson LC, **Nicol DL**. Health related quality of life in Australian men after radical prostatectomy. *Med J of Aust* 1998 May 18; 168(10): 483-486.
27. Perumalla C, **Nicol D**. Renal autotransplantation for the management of complex ureteric defects. *Aust NZ J Surg* 1998 May; 68(5): 376-379.
28. Olive C, Cheung C, **Nicol D**, Falk M. Expression of cytokine mRNA transcripts in renal cell carcinoma. *Immunology & Cell Biology* 1998 Aug; 76(4): 357-362.
29. **Nicol D**, Hirst G. Urological assessment and complications in renal transplantation. *Transplantation Reviews* 1999 Jan; 13(1): 12-22.
30. Olive C, Cheung C, **Nicol D**, Falk M. Expression of apoptotic regulatory molecules in renal cell carcinoma: elevated expression of Fas ligand. *Immunology & Cell Biology* 1999 Feb; 77(1): 11-18.
31. Teh B, Linblad K, Nord B, Kytölä S, Schalling M, Larsson C, Rapley E, Biggs P, Huddart R, Stratton M, Hii S, **Nicol D**. Familial testicular cancer: Lack of evidence for trinucleotide repeat expansions and association with PKD1 in one family. *Jnl of Medical Genetics* 1999 Apr; 36(4): 348-349.
32. Hooper J, **Nicol D**, Dickinson J, Eyre H, Scarman A, Normyle J, Stuttgen M, Douglas M, Loveland K, Sutherland G, Antalis T. Testisin, a new human serine proteinase expressed by premeiotic testicular germ cells and lost in testicular germ cell tumours. *Cancer Res* 1999 Jul 1; 59(13): 3199-3205.
33. International collaboration of trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-Urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tratamiento Oncologico (CUETO) group. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. *Lancet* 1999 Aug 14; 354(9178): 533-540.
34. Johnson AG, Rigby R, Taylor P, Jones C, Allen J, Franzen K, Falk M, **Nicol D**. The kinetics of mycophenolic acid and its glucuronide metabolite in adult renal transplant recipients. *Clin Pharmacol & Ther.* 1999 Nov; 66(5): 492-500.
35. Rae F, Bulmer B, **Nicol D**, Clements J. The human tissue kallikreins (KLKs 1-3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library. *Immunopharmacology* 1999 Dec; 45(1-3): 83-8.
36. Johnson D, Herzig K, Purdie D, Brown Al, Rigby R, **Nicol D**, Hawley C. A comparison of the effects of dialysis and renal transplantation on the survival of older uraemic patients. *Transplantation* 2000 Mar 15; 69(5): 794-799.
37. **Nicol D**, Watt A, Wood G, Ryley B, Wall D, Miller B. The Corpus Cavernosum as an alternative means of intravenous access in the emergency setting. *Aust NZ J Surg* 2000 Jul; 70(7); 511-514.
38. Herzig K, Falk M, Jonsson J, Axelsen R, Griffin A, Hawley C, Rigby R, Cobcroft R, **Nicol DL**, Powell E, Johnson DW. Novel surveillance and cure of a

- donor- transmitted lymphoma in a renal allograft recipient. *Transplantation* 2000 July 15; 70(1): 149-152.
39. **Nicol D.** Issues in the diagnosis of renal cell carcinoma. *BJU Int* 2000 Aug; 86(3): 298-303.
40. Johnson DW, Herzig KA, Purdie DM, Chang W, Brown AM, Rigby RJ, Campbell SB, **Nicol DL**, Hawley CM (2000). Is obesity a favourable prognostic factor in peritoneal dialysis patients? *Perit Dial Int.* 2000 Nov-Dec; 20(6): 715-721.
41. Rae F, Stephenson S-A, **Nicol D**, Clements J. Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. *Int J Cancer* 2000 Dec 1; 88(5): 726-732.
42. Bulmer F, Ward G, Diamandis E, **Nicol D**, Clements J. Prostaglandin D Synthase is not elevated in renal cell carcinoma. *Clin Chem* 2001 Mar; 47(3): 607-608.
43. Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, Sturtevant JM, Isbel NM, **Nicol DL**, Johnson DW (2001). Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? *J Am Soc Nephrol.* 2001 Apr; 12(4): 814-821.
44. Douglas ML, Boucaut KJ, Higgins C, Pera MF, Stuttgen MA, Antalis TM and **Nicol DL**. An orthotopic xenograft model of human non-seminomatous germ cell tumour *Br J Cancer* 2001 Aug 17; 85(4): 608-611.
45. Rae FK, Hooper JD, **Nicol DL**, Clements JA. Characterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumours. *Mol Carcinog* 2001 Sep; 32(1): 44-53.
46. Rae FK, Hopper JD, Eyre HJ, Sutherland GR, **Nicol DL**, Clements JA. TTYH2, A Human Homologue of the Drosophila Melanogaster Tweety Gene, is Located on 17q24 and Up-regulated in renal cell carcinoma. *Genomics*, 2001 Oct; 77(3): 200.
47. Takahashi M, Kahnoski R, Gross D, **Nicol D**, Teh BT. Familial adult renal neoplasia. *J Med Genet* 2002 Jan; 39(1): 1-5.
48. Douglas ML, Reid JL, Hii SI, Jonsson JR and **Nicol DL**. Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide. *BJU Int* 2002 Apr; 89(6): 591-595.
49. Johnson DW, **Nicol DL**, Brown AM, Hawley CM, Campbell SB, Wall D, Griffin AD, Isbel NM. Is Mycophenolate Mofetil Less Safe than azathioprine in elderly renal transplant recipients? *Transplantation* 2002 Apr 15; 73(7): 1158-1163.
50. **Nicol D.** Cyclophosphamide and the urinary tract. *Intern Med J* 2002 May-Jun; 32(5-6): 199-201.
51. Green HJ, Pakenham KI, Headley BC, Yaxley J, **Nicol DL**, Mactaggart PN, Swanson C, Watson RB & Gardiner RA. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomised controlled trial. *BJU Int* 2002 Sep; 90(4): 427-432.
52. Johnson DW, Isbel NM, Brown AM, Kay TD, Franzen K, Hawley CM, Campbell SB, Wall DR, Griffin AD, **Nicol DL**. The effect of obesity on renal transplant outcomes. *Transplantation* 2002 Sep 15; 74(5): 675-681.
53. Ramsay HM, Fryer AA, Hawley CM, Smith AG, **Nicol DL** and Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. *BJD* 2002; 147: 950-956.
54. Gill D, Juffs HG, Herzig KA, Brown AM, Hawley CM, Cobcroft RG, Petrie JJ, Marlton P, Kennedy G, Thomson DB, Campbell SB, **Nicol DL**, Norris D, Johnson

- DW. Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation. *Transplant Proc.* 2003 Feb; 35(1): 256-257.
55. Hrouda D, **Nicol D** and Gardiner RA. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. *Urol Res* 2003 Feb; 30(6): 347-355. (Epub 2002 Nov 21)
56. Carroll RP, Ramsay HM, Fryer AA, Hawley CM, **Nicol DL**, Harden PN. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. *Am J Kidney Dis.* 2003 Mar; 41(3): 676-683.
57. Herzig KA, Juffs HG, Norris D, Brown AM, Gill D, Hawley CM, Cobcroft R, Petrie JB, Marlton P, Thomson D, Campbell SB, Isbel NM, **Nicol DL** and Johnson DW. A single-centre experience of post-renal transplant lymphoproliferative disorder. *Transpl Int.* 2003 July; 16(7): 529-536.
58. Johnson DW, **Nicol DL**, Brown AM, Hawley CM, Campbell SB, Wall D, Griffin AD, Isbel NM. Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients. *Transplantation* 2003 Aug 15; 76(3): 619.
59. Ramsay HM, Fryer AA, Hawley CM, Smith AG, **Nicol DL** and Harden PN. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. *J Am Acad Dermatol.* 2003 Sept; 49(3): 397-406.
60. Gianduzzo TR, Holmes EG, Tinggi U, Shahin M, Mactaggart P and **Nicol DL**. Prostatic and peripheral blood selenium levels after oral supplementation. *J Urol.* 2003 Sep; 170(3): 870-873.
61. Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN, Gray SG, Knapp R, Anema J, Kahnoski R, **Nicol DL**, Vogelzang NJ, Furge KA, Kanayama H, Kagawa S and Teh BT. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. *Oncogene* 2003 Oct 2; 22(43): 6810-8.
62. Campbell SB, Hothersall E, Preston J, Brown AM, Hawley CM, Wall D, Griffin AD, Isbel NM, **Nicol DL** and Johnson DW. Frequency and severity of acute rejection in live-versus cadaveric-donor renal transplants. *Transplantation* 2003 Nov 27; 76(10): 1452-7.
63. Tinggi U, Gianduzzo T, Francis R, **Nicol D**, Shahin M, Scheelings P. Determination of selenium in red blood cells by inductively coupled plasma mass spectrometry (ICP-MS) after microwave digestion. *Journal of Radioanalytical & Nuclear Chemistry* 2004, 259(3) 469-472.
64. Mudge DW, Atcheson B, Taylor PJ, Sturtevant JM, Hawley CM, Campbell SB, Isbel NM, **Nicol DL**, Pillans PI, Johnson DW. The effect of oral iron administration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. *Transplantation.* 2004 Jan 27; 77(2): 206-209.
65. Cheung CW, Vesey DA, **Nicol DL**, Johnson DW. The roles of IGF-1 and IGFBP-3 in the regulation of proximal tubule and renal cell carcinoma cell proliferation. *Kidney International* 2004 Apr; 65(4): 1272-1279.
66. Douglas ML, Richardson MM and **Nicol DL**. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma. *Cancer* 2004 May 15; 100(10): 2118-24.
67. Green HJ, Pakenham KI, Headly BC, Yaxley J, **Nicol DL**, Mactaggart PN, Swanson C, Watson RB, Gardiner RA. Quality of life compared during

- pharmacological treatments and clinical monitoring for non-localised prostate cancer: A randomised controlled trial. *BJU Int*, 2004 May; 93(7): 975-9.
68. Campbell PA, Conrad RJ, Campbell CM, **Nicol DL** and Mactaggart P. Papillary urothelial neoplasm of low malignant potential: Reliability of diagnosis and outcome. *BJU Int*. 2004 Jun; 93(9): 1228-31.
69. Greenwell TJ, Castle C, Andrich DE, MacDonald JT, **Nicol DL** and Mundy AR. Repeat urethrotomy and dilation for the treatment of urethral stricture are neither clinically effective nor cost-effective. *J Urol* 2004 July; 172(1): 275-277.
70. Gardiner RA, **Nicol DL**, Green HJ, Yaxley J, Watson R, Mactaggart P, Headley BC, Swanson C and Pakenham KI. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. *J Urol* 2004 Aug; 172(2): 774-775.
71. Wysocki AP, Hetherington R, **Nicol D** and Gibbs HH. Haemodynamic assessment following inferior vena cava resection without replacement. *ANZ J* 2004 Aug; 74(8): 667-670.
72. Davidson K, Percy C, Rennick AJ, Pat BK, Li J, **Nicol D**, Johnson DW, Gobe GC. Comparative analysis of caspase activation and apoptosis in renal tubular epithelial cells and renal cell carcinomas. *Nephron Exp Nephrol* 2005 Feb 9; 99(4): E112-120.
73. Mudge DW, Johnson DW, Isbel NM, Campbell SB, **Nicol DL**, and Hawley CM. Obliterative bronchiolitis or opportunistic infection? A diagnostic challenge in a renal transplant patient. *Nephrol Dial Transplant* 2005 Jan; 20(1): 246-7.
74. Cheung C, Vesey D, Cotterill A, Douglas M, Gobe G, **Nicol D** and Johnson D. Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas. *Int J Urol*, 2005 Jan; 12(1): 17-28.
75. Fryer AA, Ramsay HM, Lovatt TJ, Jones PW, Hawley CM, **Nicol DL**, Strange RC and Harden PN. Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients. *Carcinogenesis* 2005 Jan; 26(1): 185-191 (Epub 2004 Sep 30).
76. Manton KJ, Douglas ML, Netzel-Arnett S, Fitzpatrick DR, **Nicol DL**, Boyd AW, Clements JA and Antalis TM. Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis. *Br J Cancer* 2005; 28, 92(4): 760-769.
77. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, **Nicol DL**, Herington AC and Clements JA. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. *Endocr Relat Cancer* 2005 Sep; 12(3): 631-643.
78. Armstrong KA, Campbell SB, Hawley CM, **Nicol DL**, Johnson DW, Isbel NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. *Am J Transplant* 2005 Nov; 5(11): 2710-8.
79. Douglas ML, Richardson MM, **Nicol DL**. Testicular germ cell tumors exhibit evidence of hormone dependence. *Int J Cancer* 2006 Jan 1; 118(1): 98-102.
80. Xiao Y, Goss B, Shi W, Forsythe M, Campbell A, **Nicol D**, Williams R and Crawford R. Laminin, VEGF and Bone Matrix Protein Expression in Uroepithelial Bone Induction-a Canine Model. *Connect Tissue Res* 2006 Mar-Apr; 47(2): 102-9.

81. Whitbread AK, Veveris-Lowe TL, Lawrence MG, **Nicol DL**, Clements JA. The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition. *Biol Chem* 2006 Jun; 387(6): 707-14.
82. Power RE, Preston JM, Griffin A, Martin I, Wall DR, **Nicol DL**. Laparoscopic vs open living donor nephrectomy: a contemporary series from one centre. *BJU Int* 2006 July; 98(1) 133-136.
83. Gardiner RA, **Nicol DL**, Green HJ, Pakenham KI. Side-effects of treatment for locally advanced prostate cancer. *BJU Int* 2006 Jul; 98(1): 229-30.
84. Johnson DW, Mudge DW, Kaiser MO, Campbell SB, Hawley CM, Isbel NM, Wall D, Griffin A, Preston J and **Nicol DL**. Deceased donor renal transplantation – does side matter? *Nephrol Dial Transplant* 2006 Sep; 21(9): 2583-2588.
85. Johnson DW, Wong J, Wiggins KJ, Kirwan R, Griffin A, Preston J, Wall D, Campbell SB, Isbel NM, Mudge DW, Hawley CM, **Nicol DL**. A randomized controlled trial of coiled versus straight swan-neck Tenckhoff catheters in peritoneal dialysis patients. *Am J Kidney Dis*. 2006 Nov; 48(5): 812-21.
86. Vela I, Gregory L, Gardiner EM, Clements JA, **Nicol DL**. Bone and prostate cancer cell interactions in metastatic prostate cancer. *BJU Int*. 2006; 99(4): 735-42.
87. Hawley CM, Kearsley J, Campbell SB, Mudge DW, Isbel NM, Johnson DW, May K, Preston J, Griffin A, Wall D, Burke J, McTaggart SJ, Forhloff G, **Nicol D**. Estimated donor glomerular filtration rate is the most important donor characteristic predicting graft function in recipients of kidneys from live donors. *Transpl Int*. 2007 Jan; 20(1): 64-72.
88. Forman CJ, Johnson DW, **Nicol DL**. Erythropoietin administration protects against functional impairment and cell death after ischaemic renal injury in pigs. *BJU Int* 2007 Jan; 99(1): 162-165.
89. Cheung CW, Vesey DA, **Nicol DL**, Johnson DW. Silibinin inhibits renal cell carcinoma via mechanisms that are independent of insulin-like growth factor-binding protein 3. *BJU Int*. 2007 Feb;99(2): 454-60.
90. Gao J, Collard RL, Bui L, Herington AC, **Nicol DL**, Clements JA. Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. *Prostate*. 2007; 67(4): 348-60.
91. Cheung CW, Taylor PJ, Kirkpatrick CM, Vesey DA, Gobe GC, Winterford C, **Nicol DL**, Johnson DW. Therapeutic value of orally administered silibinin in renal cell carcinoma manipulation of insulin-like growth factor binding protein -3 levels. *BJU Int* 2007. Aug;(2): 438-44.
92. Lawrence MG, Veveris-Lowe TL, Whitbread AK, **Nicol DL**, Clements JA. Epithelial- mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases. *Cell Tissues Organs*. 2007;185(1-3): 111-5.
93. Chambers SK, Ferguson M, Gardiner RA, **Nicol D**, Gordon L, Occhipinti S, Aitken J. Pros Can for men: randomised controlled trial of a decision support intervention for men with localised prostate cancer. *BMC Cancer*. 2008 Jul 24;8: 207.
94. **Nicol DL**, Preston JM, Wall DR, Griffin AD, Campbell SB, Isbel NM, Hawley CM, Johnson DW. Kidneys from patients with small renal tumours: a novel source of kidneys for transplantation. *BJU Int*. 2008 Jul;102(2): 188-92.
95. Steginga SK, Ferguson M, Clutton S, Gardiner RA, **Nicol DL**. Early decision and psychosocial support intervention for men with localised prostate cancer: an integrated approach. *Support Care Cancer*. 2008 Jul;16(7): 821-9.

96. Lawson M, Vasilaris A, DeAries AM, MacTaggart, **Nicol D**. Urological implication and cyclophosphamide and Ifosfamide. *Scand J Urol Nephrol* 2008;42(4):309 – 17.
97. Nicol DL, Preston JM, Wall DR, Griffin AD, Campbell SB, Isbel NM, Hawley CM, Johnson DW. Kidneys from patients with small renal tumours: a novel source of kidneys for transplantation. *BJU Int.* 2008 Jul;102(2):188-92; discussion 192-3
98. Gray K, Heathcote P, **Nicol D**. Does teaching affect outcome with major open surgery? *ANZ J. Surg* 2008 Aug, 78: 646 – 647
99. Steginga SK, Ferguson M, Clutton S, Gardiner RA, **Nicol D**. Early decision and psychosocial support intervention for men with localised prostate cancer: an integrated approach. *Support Care Cancer* 2008 Jul;16(7):821-9. Epub 2007 Oct 25
100. Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dörk T, Neal D, Cox A, Maier C, Vogel W, Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A, Steginga S, John EM, Giles G, Hopper J, Chappuis PO, Hutter P, Foulkes WD, Hamel N, Salinas CA, Koopmeiners JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL, Stern MC, Corral R, McDonnell SK, Schürmann P, Meyer A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu JF, O'Mara T, Gardiner RA, Aitken J, Joshi AD, Severi G, English DR, Southey M, Edwards SM, Al Olama AA; PRACTICAL Consortium, Eeles RA. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. *Cancer Epidemiol Biomarkers Prev.* 2008 Aug;17(8):2052-61. *(**Nicol DL**, Clements J, Members of the PRACTICAL Consortium)
101. Kaiser MO, **Nicol DL**, Hawley CM, Mudge DW, Johnson DW, Preston JM, Wall DR, Griffin AD, Campbell SB, Isbel NM. Change in live donor characteristics over the last 25 years: a single centre experience. *Nephrology* 2008 Oct;13(7):646-50.
102. Mudge DW, Tan KS, Miles R, Johnson DW, Campbell SB, Hawley CM, Isbel NM, Van Eps CL, **Nicol DL**. Intravenous versus oral iron supplementation for correction of post-transplant anaemia in renal transplant patients. *BMC Nephrol.* 2009 Jun 6;10:14.
103. Urwin HR, Jones PW, Harden PN, Ramsay HM, Hawley CM, **Nicol DL**, Fryer AA. Predicting risk of non-melanoma skin cancer and premalignant skin lesions in renal transplant recipients. *Transplantation.* 2009 Jun 15;87(11):1667-71.
104. Eeles RA et al Identification of seven new prostate cancer susceptibility loci through a genome-wide association study *Nat Genet.* 2009 Oct;41(10):1116-21
105. Brook NR, Gibbons N, Johnson DW, **Nicol DL**. Outcomes of transplants from patients with small renal tumours live unrelated donors and dialysis wait-listed patients. *Transpl Int.* 2010 May 1;23(5):476-83
106. Cheung CW, Gibbons N, Johnson DW, **Nicol DL**. Silibinin – A promising new treatment for cancer. *Anticancer Agents Med Chem.* 2010 Mar;10(3):186-95.
107. Whitbread AK, Veveris-Lowe TL, Dong Y, Tan OL, Gardiner R, Samaratunga HM, **Nicol DL**, Clements JA. Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. *Biol Chem.* 2010 Apr;391(4):461-6.
108. Brook NR, Gibbons N, **Nicol DL**, McDonald SP Open and laparoscopic donor nephrectomy: activity and outcomes from all Australasian transplant centers *Transplantation.* 2010 Jun 27;89(12):1482-8.

109. Bycroft JA, Benaragama KS, Green A, Lindsey B, **Nicol DL**. Incidental renal cell carcinoma identified during laparoscopic live-related donor nephrectomy. *JRSM Short Rep.* 2010 Sep 20;1(4):32.
110. Chen AC, Waterboer T, Keleher A, Morrison B, Jindal S, McMillan D, **Nicol D**, Gardiner RA, McMillan NA, Antonsson A. Human Papillomavirus in Benign Prostatic Hyperplasia and Prostatic Adenocarcinoma Patients. *Pathol Oncol Res.* 2011 Jan 16. [Epub ahead of print]
111. Huynh CC, Brooks AJ, **Nicol D**, Woo HH. Patients' perceptions of surgical registrars' training in the private hospital setting. *BJU Int.* 2011 Nov;108 Suppl 2:58-61
112. Brown S, Lehman M, Ferrari-Anderson J, Glyde A, Burmeister E, **Nicol D**. Assessment of prostatic fiducial marker introduction. *J Med Imaging Radiat Oncol.* 2011 Aug;55(4):417-24
113. **Nicol D**, Fujita S. Kidneys from patients with small renal tumours used for transplantation: outcomes and results. *Curr Opin Urol.* 2011 Sep;21(5):380-5
114. Banga N, **Nicol D**. Techniques in laparoscopic donor nephrectomy *BJU Int.* 2012 2012 Nov;110(9):1368-73
115. Gupta S, Correa G, Al-Akraa M, **Nicol D**, Burns A. Managing massive renal angiomyolipoma. *JRSM Short Rep.* 2012 Apr;3(4):27
116. M.A. Goldstraw, D.L. Nicol. Renal cell carcinoma: The management of the small renal mass *Brit J Med and Surg Urology* 2012, Pages 312–321
117. Lienert AR, **Nicol D**. Renal Angiomyolipoma *BJU Int.* 2012 Dec;110 Suppl 4:25-7
118. Horwich A, **Nicol D**, Huddart R. Testicular germ cell tumours. *BMJ.* 2013 Sep 24;347:
119. Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N, Rowan AJ, Hazell S, Hamm D, Robins HS, Pickering L, Gore M, **Nicol DL**, Larkin J, Swanton C. Ultra-deep T-cell receptor sequencing reveals the complexity and intratumour heterogeneity of T-cell clones in renal cell carcinomas *J Pathol.* 2013 Oct 1. [Epub ahead of print]
120. Vela I, Morrissey C, Zhang X, Chen S, Corey E, Stratton GM, Nelson CC, **Nicol DL**, Clements JA, Gardiner EM. PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer. *Clin Exp Metastasis.* 2014 Feb;31(2):199-211
121. **Nicol D** Editorial comment on 'Contemporary management of renal cell carcinoma in Victoria: implications for longer term outcomes and costs'. *BJU Int.* 2013 Nov;112 Suppl 2:44-5
122. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, Martinez P, Phillimore B, Begum S, Rabinowitz A, Spencer-Dene B, Gulati S, Bates PA, Stamp G, Pickering L, Gore M, **Nicol DL**, Hazell S, Futreal PA, Stewart A, Swanton C. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. *Nat Genet.* 2014 Mar;46(3):225-33
123. Stewart GD, Harrison DJ, Swanton C, Lewis R, Bliss J, Larkin J, **Nicol DL**; A-PREDICT TMG. Multidisciplinary urological engagement in translational renal cancer research. *BJU Int.* 2014 Oct;114(4):474-5
124. Fisher R, Horswell S, Rowan A, Salm MP, de Bruin EC, Gulati S, McGranahan N, Stares M, Gerlinger M, Varela I, Crockford A, Favero F, Quidville V, André F, Navas C, Grönroos E, **Nicol D**, Hazell S, Hrouda D, O'Brien T, Matthews N, Phillimore B, Begum S, Rabinowitz A, Biggs J, Bates PA, McDonald

NQ, Stamp G, Spencer-Dene B, Hsieh JJ, Xu J, Pickering L, Gore M, Larkin J, Swanton C. Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. *Genome Biol.* 2014 Aug 27;15(8):433

125. Manning TG, Roach TS, Papa N, Bolton DM, Sengupta S, Nicol D, Lawrentschuk N. Urological Society of Australia and New Zealand's alignment with the BJU International: a collaborative success magnified by a supplement journal. *BJU Int.* 2014 Nov;114 Suppl 1:3-5

126. Benaragama SK, Tymkewycz T, John BJ, Davenport A, Lindsey B, Nicol D, Olsburgh J, Drage M, Mamode N, Calder F, Taylor J, Koffman G, Kessarar N, Morsy M, Cacciola R, Puliatti C, Fernadez-Diaz S, Syed A, Hakim N, Papalois V, Fernando BS. Do we need a different organ allocation system for kidney transplants using donors after circulatory death? *BMC Nephrol.* 2014 May 22;15:83.

127. Chung E, Yang S, White L, Wood S, Nicol D. Lessons learnt in the management of primary invasive penile cancer in an Australian tertiary referral centre: clinical outcomes with a minimum 48 months follow-up study. *Korean J Urol.* 2015 Feb;56(2):125-30

128. Kovac M, Navas C, Horswell S, Salm M, Bardella C, Rowan A, Stares M, Castro-Giner F, Fisher R, de Bruin EC, Kovacova M, Gorman M, Makino S, Williams J, Jaeger E, Jones A, Howarth K, Larkin J, Pickering L, Gore M, Nicol DL, Hazell S, Stamp G, O'Brien T, Challacombe B, Matthews N, Phillimore B, Begum S, Rabinowitz A, Varela I, Chandra A, Horsfield C, Polson A, Tran M, Bhatt R, Terracciano L, Eppenberger-Castori S, Protheroe A, Maher E, El Bahrawy M, Fleming S, Ratcliffe P, Heinemann K, Swanton C, Tomlinson I. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. *Nature Commun.* 2015 Mar 19;6:6336

129. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, Dennis N, Merson S, Leongamornlert D, Zamora J, Corbishley C, Thomas S, Nik-Zainal S, O'Meara S, Matthews L, Clark J, Hurst R, Mithen R, Bristow RG, Boutros PC, Fraser M, Cooke S, Raine K, Jones D, Menzies A, Stebbings L, Hinton J, Teague J, McLaren S, Mudie L, Hardy C, Anderson E, Joseph O, Goody V, Robinson B, Maddison M, Gamble S, Greenman C, Berney D, Hazell S, Livni N; ICGC Prostate Group, Fisher C, Ogden C, Kumar P, Thompson A, Woodhouse C, Nicol D, Mayer E, Dudderidge T, Shah NC, Gnanapragasam V, Voet T, Campbell P, Futreal A, Easton D, Warren AY, Foster CS, Stratton MR, Whitaker HC, McDermott U, Brewer DS, Neal DE. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. *Nat Genet.* 2015 Apr;47(4):367-72

130. Gardiner RA, Yaxley J, Pakenham KI, Green H, Mactaggart P, Watson R, Swanson C, Nicol DL. Patients Who Receive Androgen Deprivation Therapy Risk Adverse Cognitive Changes. *J Clin Oncol.* 2015 Dec 20;33(36):4314-5.

131. Greenwell TJ, Castle C, Nicol DL. Clean intermittent self-catheterization does not appear to be effective in the prevention of urethral stricture recurrence. *Scand J Urol.* 2016 Feb;50(1):71-3

132. Ap Dafydd D, Messiou C, Thway K, Strauss DC, Nicol DL, Moskovic E. Paratesticular Sarcoma: Typical Presentation, Imaging Features, and Clinical Challenges. *Urology.* 2017 Feb;100:163-168.

133. Rossi SH, Hsu R, Blick C, Goh V, Nathan P, **Nicol D**, Fleming S, Sweeting M, Wilson EC, Stewart GD. Meta-analysis of the prevalence of renal cancer detected by abdominal ultrasonography. *Br J Surg*. 2017 May;104(6):648-659.
134. Sweeting M, Wilson EC, Stewart GD. *Br J Surg*. 2017 May;104(6):648-659. Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, **Nicol D**, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. *Immunity*. 2017 Apr 18;46(4):577-586.
135. Wei X, Choudhury Y, Lim WK, Anema J, Kahnoski RJ, Lane B, Ludlow J, Takahashi M, Kanayama HO, Beldegrun A, Kim HL, Rogers C, **Nicol D**, Teh BT, Tan MH. Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma. *Sci Rep*. 2017 Aug 4;7(1):7342.
136. Camacho N, Van Loo P, Edwards S, Kay JD, Matthews L, Haase K, Clark J, Dennis N, Thomas S, Kremeyer B, Zamora J, Butler AP, Gundem G, Merson S, Luxton H, Hawkins S, Ghori M, Marsden L, Lambert A, Karaszi K, Pelvender G, Massie CE, Kote-Jarai Z, Raine K, Jones D, Howat WJ, Hazell S, Livni N, Fisher C, Ogden C, Kumar P, Thompson A, **Nicol D**, Mayer E, Dudderidge T, Yu Y, Zhang H, Shah NC, Gnanapragasam VJ; CRUK-ICGC Prostate Group, Isaacs W, Visakorpi T, Hamdy F, Berney D, Verrill C, Warren AY, Wedge DC, Lynch AG, Foster CS, Lu YJ, Bova GS, Whitaker HC, McDermott U, Neal DE, Eeles R, Cooper CS, Brewer DS. Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. *PLoS Genet*. 2017 Sep 25;13(9):e1007001. doi: 10.1371/journal.pgen.1007001. eCollection 2017 Sep.
137. Kass-Iliyya A, Jovic G, Murphy C, Fisher C, Syndikus I, Jose C, Scrase CD, Graham JD, **Nicol D**, Sydes MR, Dearnaley D. Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial. *Eur Urol*. 2018 Jun;73(6):968-976.
138. Mitchell TJ*, Turajlic S*, Rowan A*, **David Nicol***, James HR Farmery, Tim O'Brien, Inigo Martincorena, Patrick Tarpey, Nicos Angelopoulos, Lucy R Yates, Adam P Butler, Keiran Raine, Grant D Stewart, Ben Challacombe, Archana Fernando, Jose I Lopez, Steve Hazell, Ashish Chandra, Simon Chowdhury, Sarah Rudman, Aspasia Soultati, Gordon Stamp, Nicos Fotiadis, Lisa Pickering, Lewis Au, Lavinia Spain, Joanna Lynch, Mark Stares, Jon Teague, Francesco Maura, David C Wedge, Stuart Horswell, Tim Chambers, Kevin Litchfield, Hang Xu, Aengus Stewart, Reza Elaidi, Stéphane Oudard, Nicholas McGranahan, Istvan Csabai, Martin Gore, P Andrew Futreal, James Larkin, Andy G Lynch, Zoltan Szallasi, Charles Swanton, Peter J Campbell. Timing the landmark events in the evolution of clear cell renal cell carcinoma. *Cell Volume 173, Issue 3, 19 April 2018, 611-623. * Joint first author*
139. **Nicol D**. Comparison of UK and European Association of Urology (EAU) guidelines for kidney cancer management. *J Clin Urol February 1, 2018; pp. 132-138*.
140. Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, **Nicol D**, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendeus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S,

Swanton C, Peggs KS, Quezada SA. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. *Cancer Cell*. 2018 Apr 9;33(4):649-663

141. Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentre S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, **Nicol D**, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C; CAMCAP Study Group, de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C; TCGA Consortium, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. *Nat Genet*. 2018 May;50(5):682-692.

142. Turajlic S*, Xu H*, Litchfield K*, Rowan A*, Chambers T*, Lopez JI*, **Nicol D***, O'Brien T*, Larkin J*, Horswell S, Stares M, Au L, Jamal-Hanjani M, Challacombe B, Chandra A, Hazell S, Eichler-Jonsson C, Soultati A, Chowdhury S, Rudman S, Lynch J, Fernando A, Stamp G, Nye E, Jabbar F, Spain L, Lall S, Guarch R, Falzon M, Proctor I, Pickering L, Gore M, Watkins TBK, Ward S, Stewart A, DiNatale R, Becerra MF, Reznik E, Hsieh JJ, Richmond TA, Mayhew GF, Hill SM, McNally CD, Jones C, Rosenbaum H, Stanislaw S, Burgess DL, Alexander NR, Swanton C; PEACE; TRACERx Renal Consortium. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. *Cell*. 2018 Apr 19;173(3):581-594. * **Joint first author**

143. Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, O'Brien T, Lopez JI, Watkins TBK, **Nicol D**, Stares M, Challacombe B, Hazell S, Chandra A, Mitchell TJ, Au L, Eichler-Jonsson C, Jabbar F, Soultati A, Chowdhury S, Rudman S, Lynch J, Fernando A, Stamp G, Nye E, Stewart A, Xing W, Smith JC, Escudero M, Huffman A, Matthews N, Elgar G, Phillimore B, Costa M, Begum S, Ward S, Salm M, Boeing S, Fisher R, Spain L, Navas C, Grönroos E, Hobor S, Sharma S, Aurangzeb I, Lall S, Polson A, Varia M, Horsfield C, Fotiadis N, Pickering L, Schwarz RF, Silva B, Herrero J, Luscombe NM, Jamal-Hanjani M, Rosenthal R, Birkbak NJ, Wilson GA, Pipek O, Ribli D, Krzystanek M, Csabai I, Szallasi Z, Gore M, McGranahan N, Van Loo P, Campbell P, Larkin J, Swanton C; TRACERx Renal Consortium. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. *Cell*. 2018 Apr 19;173(3):595-610

144. Bellini MI, Gopal JP, Hill P, **Nicol D**, Gibbons N. Urothelial carcinoma arising from the transplanted kidney: A single-center experience and literature review. *Clin Transplant*. 2019 Apr 3:e13559. doi: 10.1111/ctr.13559. [Epub ahead of print]

